

CELLULOSE AC TOSSE

TABLETING →
DIRECT COMPRESSION →
CO-PROCESSED LACTOSE

Technical brochure
Cellactose® 80



MEGGLE co-processed lactose grades for direct compression: Cellactose® 80

General information

Direct compression (DC) tablet manufacture is a popular choice because it provides the least complex, most cost effective process to produce tablets compared to other tablet manufacturing approaches. Manufacturers can blend APIs with excipients and compress, making dosage forms simple to produce [1, 2].

DC technology and the use of modern tableting equipment require that excipients and APIs form a compactable mixture with excellent flowability and low particle segregation tendency [3].

In the pharmaceutical industry, lactose is one of the most commonly used excipients; however, like many other excipients, lactose may not be suitable for direct compression without modification due to insufficient powder flow or/and compaction properties (**Figure 1**).

Product description

Alpha-lactose monohydrate and cellulose powder are functional excipients used in oral solid dosage forms. Both are naturally derived and well-established for use in the pharmaceutical industry. In an effort to create synergistic functional performance, such as improved compactability and mixing characteristics, co-spray-drying was used to integrate alpha-lactose monohydrate and cellulose powder into a monoparticulate system. Cellactose® 80 was developed to provide the flow and compaction properties necessary for direct compression tableting. Cellactose® 80 comprises 75% alpha-lactose monohydrate and 25% powdered cellulose, both maintaining their individual chemical identities.




Figure 1: Powder blend compressibility and flowability requirements for various tableting technologies (DC is direct compression, WG is wet granulation, DG is dry granulation) [3].

Regulatory & quality information

The raw materials used to produce Cellactose® 80, alpha-lactose monohydrate and cellulose powder, meet Ph.Eur., USP-NF, and JP monograph requirements. Since no chemical modifications result during co-processing and individual chemical identities are maintained, Cellactose® 80 can be considered as a physical blend of alpha-lactose monohydrate and cellulose powder. In addition, a Cellactose® 80 drug master file (DMF) is available during FDA (Food and Drug Administration) drug product submission review and approval. Specifications and regulatory documents can be downloaded from www.meggle-pharma.com.

Our pharma-dedicated production facility in Wasserburg, Germany is certified according to DIN ISO 9001:2008, has implemented cGMP according to the Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients, and USP General Information Chapter <1078>. The Wasserburg facility demonstrates MEGGLE's complete lactose production capability range, including sieving, milling, agglomeration, spray-drying, and co-processing. Additionally, MEGGLE is a member of IPEC (International Pharmaceutical Excipients Council).

MEGGLE invests considerably in raw material resource sustainability, production standards, efficiency and is actively engaged in environmental protection. Excipients meeting pharmaceutical standards is our first priority.

Application

Cellactose® 80 is designed for direct compression tableting and may be used in other formulation applications such as dry granulation and capsule filling. In comparison with a corresponding physical blend of the individual components, Cellactose® 80 provides improved compactability, superior flowability, and increased adherence capacity, which reduces segregation tendencies typical of simple powder blends. Due to improved blending characteristics and increased adherence capacity, Cellactose® 80 is ideal for low-dose formulations. Cellactose® 80's superior compaction properties increases tablet hardness in high-dose formulations as well. For low-dose or high-dose applications, Cellactose® 80 maximizes formulation development flexibility.

- Direct compression
- Low dosage formulations
- High dosage formulations

BENEFITS

Cellactose® 80

- Excellent compactability
- Excellent flowability
- Tableting of delicate APIs
- High API adherence capacity
- Ideal tablet surface for easy and economical coating

Particle size distribution (PSD)

Figure 2 shows typical laser diffraction particle size distribution data for Cellactose® 80. Cellactose® 80 possesses a narrow PSD that is effective in preparing homogenous powder blends, a prerequisite in achieving good tablet quality.





Figure 2: Typical cumulative PSD and distribution density of MEGGLE’s Cellactose® 80. Analyzed by Sympatec®/Helos & Rodos particle size analyzer.

Figure 3 depicts the specified PSD range and typical average values by air jet sieving. These parameters are constantly monitored through in-process-control (IPC) testing and are part of the Cellactose® 80 particle size distribution specification.



Sieve data – co-processed lactose		
	Lactose type	Cellactose® 80
		specified/typical
Particle size distribution	< 32 µm	NMT 20 %/7 %
Method:	< 160 µm	35 – 65 %/54 %
Air jet sieving	< 250 µm	NLT 80 %/93 %

Figure 3: Specified PSDs for Cellactose® 80 by air jet sieve in bold letters. Typical values obtained from a permanent in-process-control are shown for orientation.

Batch-to-batch consistency

Batch-to-batch consistency for all lactose products can be attributed to MEGGLE's long history and experience in lactose manufacture, and broad technical expertise. Constant in-process and final product testing ensures consistency and quality (Figure 4).




Figure 4: Cellactose® 80 particle size distribution batch-to-batch consistency by air jet sieve analysis. Data obtained from a permanent in-process-control (IPC) of subsequent batches over 12 months.

Isotherms

Cellactose® 80 exhibits moderate moisture uptake under high relative humidity conditions due to the cellulose powder influence on the observed equilibrium moisture content (Figure 5).




Figure 5: Sorption-desorption isotherm of Cellactose® 80.




Figure 6: SEM image of MEGGLE's Cellactose® 80.

Scanning electron micrograph (SEM)

Cellactose® 80 is nearly spherical in shape due to the co-spray-drying manufacturing process. Cellactose® 80's overall morphology reduces blend segregation and improves finished dosage form content uniformity (Figure 6).

Functional related characteristics

Powder flow

In assessing powder flow using a FlowRatex® apparatus, Cellactose® 80 exhibited superior flowability compared to a physical blend, made up of spray-dried lactose and powdered cellulose. The simple blend of individual ingredients showed greater flow variation compared to Cellactose® 80 (**Figure 7**). Cellactose® 80 also possessed lower flowability index (Cellactose® 80 = 5 mm, physical blend = 24 mm), indicating superior flowability (**Figure 8**).

Flowability can also be described by the Hausner ratio, Carr's index, or angle of repose. A Hausner ratio below 1.25 or Carr's index below 20 indicates that powders are freely flowing. Angle of repose describes "good flowability" between 31–35°, and in general, worsens with steeper angles. **Figure 9** shows typical flowability indices for Cellactose® 80, indicating excellent flowability.




Figure 7: Volume flow rate (ml/s) as a function of aperture size (mm diameter) for Cellactose® 80 and a comparable physical blend analyzed by a FlowRatex®.




Figure 8: Flowability index of Cellactose® 80 and its corresponding physical blend. Smaller values indicate better flowability.

Flowability					
Co-processed lactose					
	Angle of repose (°)	Density bulk (g/l)	Density tapped (g/l)	Hausner ratio	Carr's index (%)
Cellactose® 80	34	370	490	1.32	24.49

Figure 9: Flowability/processability related parameters of Cellactose® 80.





Figure 10: Tablet hardness profile for Cellactose® 80 compared to a physical blend of the individual components and Tablettose® 80 (granulated lactose). Tablets were produced using a tablet press: IMA Styl'one fitted with 11.3 mm punches. Average tablet weight was targeted at 500 mg.

Compactability

High-dose Vitamin C formulation with Cellactose® 80

Tablet hardness (N)




Cellactose® 80 Tablet press: Korsch EK 0, Tablets: Ø 8 mm, 240 mg

Friability

Co-processed Cellactose® 80

Friability (%)



Cellactose® 80 Tablettose® 80 + powdered cellulose 75:25

Figure 11: Tablet hardness profile for tablets comprising 69 % Vitamin C, 30 % Cellactose® 80, and 1 % Compritol 888. Tablets were produced by Korsch EK 0 tablet press fitted with 8 mm punches. Average tablet weight was targeted at 240 mg.

Figure 12: Friability of tablets produced with either Cellactose® 80 or its corresponding physical blend.


Adherence capacity

Due to its surface roughness, Cellactose® 80 provides high adherence capacity and is highly recommended for low dosage formulations. Cellactose® 80 mitigates powder segregation during production and assures content uniformity of finished dosage forms. To demonstrate adherence capacity, glibenclamide was blended with different excipients. Non-adhered API was removed by mechanical means, and remaining API was quantified. The following results underscore Cellactose® 80's superior adherence capacity relative to other excipients (**Figure 13**), [4].

Adherence capacity

Content uniformity – Cellactose® 80 vs. various excipients

API content (%)



Avicel PH 200 Ludipress Karion Instant Cellactose® 80

Figure 13: Adherence capacity of different excipients [4].

Packaging and shelf life

Packaging material complies with Regulation (EC) No. 1935/2004 and 21 CFR 174, 175, 176, 177 and 178. Stability tests have been performed according to ICH guidelines and an ongoing stability program is implemented. **Figure 14** provides an overview about packaging size and material, and product shelf life.

Packaging and shelf life

Cellactose® 80

	Size	Material	Shelf life
Cellactose® 80	20 kg	Paper bag with PE-EVOH-PE-inliner	36 months
		Carton box with PE-EVOH-PE-inliner	

Figure 14: Packaging and shelf life of MEGGLE's Cellactose® 80.

Literature

- [1] Meeus, L. (2011). Direct Compression versus Granulation. *Pharmaceutical Technology*, 23(3).
- [2] Kristensen, H. G., & Schaefer, T. (1987). Granulation: A Review on Pharmaceutical Wet-Granulation. *Drug Development and Industrial Pharmacy*, 13(4–5), 803–872.
- [3] Mîinea, L. A., Mehta, R., Kallam, M., Farina, J. A., & Deorkar, N. (2011). Evaluation and Characteristics of a New Direct Compression Performance Excipient, 35(3).
- [4] Schmidt and Rubensdörfer (1994). Evaluation of Ludipress as a "Multipurpose Excipient" for DC Part I: Powder Characteristics and Tableting Properties, *Drug dev. ind. Pharm.* 20(18), 2899–2925

MEGGLE App:



MEGGLE Consultant

MEGGLE Group Wasserburg
BG Excipients & Technology
 Megglestrasse 6–12
 83512 Wasserburg
 Germany

Phone +49 8071 73 476
 Fax +49 8071 73 320
service.pharma@meggle.de
www.meggle-pharma.com

MEGGLE warrants that its products conform to MEGGLE's written specification and makes no other expressed or implied warranties or representations. For any specific usage, the determination of suitability of use or application of MEGGLE products is the sole responsibility of the user. The determination of the use, application, and compliance of this product with regard to any national, regional, or local laws and/or regulations is the sole responsibility of the user, and MEGGLE makes no representation with regards to same. Nothing herein shall be construed as a recommendation or license to use the product or any information that conflicts with any patent or intellectual property of MEGGLE or others and any such determination of use is the sole responsibility of the user. © MEGGLE

US 03-27-2014 Sai